- Home
- GSBC vs OMER Comparison
GSBC vs OMER Comparison
Compare GSBC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSBC
- OMER
- Stock Information
- Founded
- GSBC 1923
- OMER 1994
- Country
- GSBC United States
- OMER United States
- Employees
- GSBC N/A
- OMER N/A
- Industry
- GSBC Major Banks
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- GSBC Finance
- OMER Health Care
- Exchange
- GSBC Nasdaq
- OMER Nasdaq
- Market Cap
- GSBC 627.5M
- OMER 628.9M
- IPO Year
- GSBC N/A
- OMER 2009
- Fundamental
- Price
- GSBC $60.66
- OMER $9.41
- Analyst Decision
- GSBC Hold
- OMER Strong Buy
- Analyst Count
- GSBC 2
- OMER 5
- Target Price
- GSBC $59.50
- OMER $27.50
- AVG Volume (30 Days)
- GSBC 47.0K
- OMER 1.7M
- Earning Date
- GSBC 10-15-2025
- OMER 11-13-2025
- Dividend Yield
- GSBC 2.84%
- OMER N/A
- EPS Growth
- GSBC 18.31
- OMER N/A
- EPS
- GSBC 6.00
- OMER N/A
- Revenue
- GSBC $228,683,000.00
- OMER N/A
- Revenue This Year
- GSBC N/A
- OMER N/A
- Revenue Next Year
- GSBC N/A
- OMER N/A
- P/E Ratio
- GSBC $10.08
- OMER N/A
- Revenue Growth
- GSBC 7.86
- OMER N/A
- 52 Week Low
- GSBC $47.58
- OMER $2.95
- 52 Week High
- GSBC $66.98
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- GSBC 61.53
- OMER 64.25
- Support Level
- GSBC $55.37
- OMER $8.04
- Resistance Level
- GSBC $59.26
- OMER $10.00
- Average True Range (ATR)
- GSBC 1.34
- OMER 0.68
- MACD
- GSBC 0.41
- OMER 0.17
- Stochastic Oscillator
- GSBC 93.25
- OMER 83.78
About GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.